

ASX ANNOUNCEMENT

21 November 2022

Share Purchase Plan open to eligible shareholders



Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce its Share Purchase Plan offer (**SPP Offer**) to eligible shareholders to subscribe for ordinary shares and free-attaching options opens today. The SPP Offer is open to all eligible shareholders who held shares in the Company on 1 November 2022.

The offer documentation also contains an offer of free-attaching options to participants in the Company's successful \$4m placement announced on 2nd November 2022 (**Placement Options Offer**).

A copy of the letter to shareholders and Offer documentation are attached to this announcement. The Offers are open from 21 November 2022 until closing at 5pm (AWST) on Monday, 19 December 2022. Further information in relation to the Offers, including frequently asked questions, can be found on the Company's investor website: <https://investor.littlegreenpharma.com/site/investor-centre/share-purchase-plan-ssp-2022>. Alternatively, eligible shareholders are invited to contact the Company on info@littlegreenpharma.com or alternatively at 1300 703 999 (Australia) or +61 8 6280 0050 (International)

ENDS
BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to be "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer

Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp